The World Health Organisation’s Executive Board (WHO EB) is currently holding its 144th session from 24 January until 1 February in Geneva to discuss its 13th General Programme of Work and to review a proposed new five-year WHO strategy for action on Health.
We are very excited that this year’s WHO EB is also focusing one of their sessions on substandard and falsified medical products! The agenda item 6.2 will be on 30th February, and will provide insights on ‘Member State mechanism on substandard and falsified medical products’.
Fight the Fakes partners, the International Council of Nurses (ICN) and International Pharmaceutical Students’ Federation (IPSF) are scheduled to deliver strong statements on the importance of fighting #fakemeds, and both are giving a shout-out to our campaign!
Don’t miss them 30th February and tune in -> www.who.int/news-room/events/executive-board-144th-session
The ICN is particularly emphasizing the need to see the issue of falsified medicines as ‘a symptom of a larger problem’, namely a lack of access to high-quality, affordable and effective healthcare. The Council is encouraging the Member State Mechanism to engage with our campaign and to foster collaborative action with important stakeholders in the fight against fake medicines.
IPSF is lending its voice to over 350,000 pharmacy students and recent graduates in 90 countries worldwide and as members of Fight the Fakes campaign want to ‘raise awareness on the dangers of falsified medicines and empower people to act on this issue’. Further collaboration with WHO to drive forward the endeavours of its Member State Mechanism is seen as critical as IPSF believes in a ‘holistic approach encompassing collaboration between all stakeholders involved in the manufacture and distribution of medicines [as being] essential in our fight against substandard and falsified medicines’.